Sugi Predict

Sugi Predict / Compounds / SCHEMBL2821181

SCHEMBL2821181

SCHEMBL2821181

CC(C)(C)OC(=O)N1CCC2(CC1)CN(C(=O)OCc1ccccc1)CCO2

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 3/20 0.54
▸ KMT2A Q03164 3/20 0.54
▸ NPSR1 Q6W5P4 2/20 0.54
▸ MGLL Q99685 3/20 0.49
▸ GPR119 Q8TDV5 1/20 0.46
▸ SMN1; SMN2 Q16637 3/20 0.45
▸ NPC1 O15118 2/20 0.45
▸ RAB9A P51151 2/20 0.45
▸ HTT P42858 1/20 0.44
▸ TACR1 P25103 1/20 0.44
▸ OPRD1 P41143 1/20 0.44
▸ OPRK1 P41145 1/20 0.44
▸ CYP2C19 P33261 1/20 0.43
▸ CHRM2 P08172 1/20 0.43
▸ CHRM3 P20309 1/20 0.43
▸ SCD5 Q86SK9 1/20 0.43
▸ ENPP2 Q13822 1/20 0.42
▸ ATXN2 Q99700 1/20 0.42
▸ KDM4E B2RXH2 1/20 0.42
▸ ALDH1A1 P00352 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30869854 0.97 MEN1 (0.52) MEN1KMT2ANPSR1MGLLGPR119
SCHEMBL31579558 0.89 YAP1 (0.48) MEN1KMT2ANPSR1MGLLGPR119
SCHEMBL15958479 0.87 MEN1 (0.59) MEN1KMT2ANPSR1MGLLSMN1; SMN2
SCHEMBL15399354 0.87 MEN1 (0.59) MEN1KMT2ANPSR1MGLLSMN1; SMN2
SCHEMBL15958476 0.87 MEN1 (0.59) MEN1KMT2ANPSR1MGLLSMN1; SMN2
SCHEMBL30155294 0.86 MEN1 (0.46) MEN1KMT2ANPSR1MGLLGPR119
SCHEMBL31579624 0.85 MGLL (0.46) MEN1KMT2ANPSR1MGLLGPR119
SCHEMBL17608925 0.85 CHRM2 (0.60) MGLLCHRM2CHRM3
SCHEMBL2629479 0.85 CYP11B2 (0.53) MEN1KMT2ANPSR1SMN1; SMN2NPC1
SCHEMBL26690753 0.83 MEN1 (0.66) MEN1KMT2ANPSR1MGLLSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260041671-A1 BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE ARVINAS OPERATIONS INC (US) 2026-02-12 — — US disclosed
US-12539292-B2 BRM targeting compounds and associated methods of use ARVINAS OPERATIONS, INC. (US) 2026-02-03 — — US disclosed
EP-4537905-A2 BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE Arvinas Operations, Inc. (US) 2025-04-16 — — EP disclosed
EP-3774789-B1 BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE ARVINAS OPERATIONS INC (US) 2025-03-05 — — EP disclosed
US-20240076295-A1 BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE GENENTECH, INC. 2024-03-07 — — US disclosed
EP-4038066-A1 BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE Arvinas Operations, Inc. (US) 2022-08-10 — — EP disclosed
CN-114787159-A BRM targeting compounds and related methods of use 阿尔维纳斯运营股份有限公司 2022-07-22 — — CN disclosed
US-20210196710-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR ARVINAS OPERATIONS, INC. 2021-07-01 — — US disclosed
WO-2021067606-A1 BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE ARVINAS OPERATIONS, INC. (US) 2021-04-08 — — WO disclosed
EP-3774789-A1 BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE Arvinas Operations, Inc. (US) 2021-02-17 — — EP disclosed
US-20200038378-A1 BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE GENENTECH, INC. 2020-02-06 — — US disclosed
WO-2019195201-A1 BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE ARVINAS OPERATIONS, INC. (US) 2019-10-10 — — WO disclosed
US-20190300521-A1 BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE GENENTECH, INC. 2019-10-03 — — US disclosed
US-20130096100-A1 DI(ARYLAMINO)ARYL COMPOUND ASTELLAS PHARMA INC. (JP) 2013-04-18 — — US disclosed
US-20130096100-A1 DI(ARYLAMINO)ARYL COMPOUND ASTELLAS PHARMA INC. (JP) 2013-04-18 — — US disclosed
US-8318702-B2 Di(arylamino)aryl compounds ASTELLAS PHARMA INC. (JP) 2012-11-27 — — US disclosed
US-20100099658-A1 DI(ARYLAMINO)ARYL COMPOUND ASTELLAS PHARMA INC. (JP) 2010-04-22 — — US disclosed
EP-2172461-A1 DI(ARYLAMINO)ARYL COMPOUND Astellas Pharma Inc. (JP) 2010-04-07 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130096100-A1 DI(ARYLAMINO)ARYL COMPOUND ERBB4, EGFR, ALK MEN1 3439/4885KMT2A 1392/4885NPSR1 3024/4885
US-20100099658-A1 DI(ARYLAMINO)ARYL COMPOUND ERBB4, EGFR, ALK MEN1 3439/4885KMT2A 1392/4885NPSR1 3024/4885
US-20240076295-A1 BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE ADRM1, BRAP, VHL MEN1 2768/4885KMT2A 874/4885NPSR1 4298/4885
US-12539292-B2 BRM targeting compounds and associated methods of use ADRM1, SUMO2, BAZ1A MEN1 3886/4885KMT2A 1067/4885NPSR1 4099/4885
US-20200038378-A1 BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE ADRM1, BRAP, VHL MEN1 2768/4885KMT2A 874/4885NPSR1 4298/4885
US-20190300521-A1 BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE ADRM1, BRAP, VHL MEN1 2768/4885KMT2A 874/4885NPSR1 4298/4885
US-20260041671-A1 BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE ADRM1, VHL, BAZ1A MEN1 4186/4885KMT2A 928/4885NPSR1 4041/4885
US-20210196710-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR AR, KLK3, ACP3 MEN1 1919/4885KMT2A 2143/4885NPSR1 298/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.